Chapter 14 References

1. Lemmens CMC, Vanhommerig JW, Knottnerus BJ, Uitdehaag BMJ, Mostert JP, Jong BA de. Prevalence and incidence of multiple sclerosis in the netherlands. Mult Scler Relat Disord. 2025;93:106207. https://doi.org/10.1016/j.msard.2024.106207.

2. Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8. https://doi.org/10.1101/cshperspect.a028928.

3. University of California SFMSET, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499–510. https://doi.org/10.1002/ana.24747.

4. Inojosa H, Proschmann U, Akgun K, Ziemssen T. A focus on secondary progressive multiple sclerosis (SPMS): Challenges in diagnosis and definition. J Neurol. 2021;268:1210–21. https://doi.org/10.1007/s00415-019-09489-5.

5. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83:278–86. https://doi.org/10.1212/WNL.0000000000000560.

6. Kuhlmann T, Ludwin S, Prat A, Antel J, Bruck W, Lassmann H. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017;133:13–24. https://doi.org/10.1007/s00401-016-1653-y.

7. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8. https://doi.org/10.1101/cshperspect.a028936.

8. Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol. 2022. https://doi.org/10.1038/s41577-022-00718-z.

9. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88. https://doi.org/10.1056/NEJMoa0706383.

10. Li R, Patterson KR, Bar-Or A. Reassessing b cell contributions in multiple sclerosis. Nat Immunol. 2018;19:696–707. https://doi.org/10.1038/s41590-018-0135-x.

11. Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobeus E, Jensen MB, et al. Smouldering multiple sclerosis: The ’real MS’. Ther Adv Neurol Disord. 2022;15:17562864211066751. https://doi.org/10.1177/17562864211066751.

12. Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobeus E, Jensen MB, et al. Smouldering multiple sclerosis: The ’real MS’. Ther Adv Neurol Disord. 2022;15:17562864211066751. https://doi.org/10.1177/17562864211066751.

13. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93. https://doi.org/10.1002/ana.22230.

14. Soldan SS, Lieberman PM. Epstein-barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21:51–64. https://doi.org/10.1038/s41579-022-00770-5.

15. Vietzen H, Berger SM, Kuhner LM, Furlano PL, Bsteh G, Berger T, et al. Ineffective control of epstein-barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell. 2023;186:5705–5718 e13. https://doi.org/10.1016/j.cell.2023.11.015.

16. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of epstein-barr virus associated with multiple sclerosis. Science. 2022;375:296–301. https://doi.org/10.1126/science.abj8222.

17. Nielsen NM, Westergaard T, Rostgaard K, Frisch M, Hjalgrim H, Wohlfahrt J, et al. Familial risk of multiple sclerosis: A nationwide cohort study. Am J Epidemiol. 2005;162:774–8. https://doi.org/10.1093/aje/kwi280.

18. Montalban X, Lebrun-Frenay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24:850–65. https://doi.org/10.1016/S1474-4422(25)00270-4.

19. Barkhof F, Reich DS, Oh J, Rocca MA, Li DKB, Sati P, et al. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol. 2025;24:866–79. https://doi.org/10.1016/S1474-4422(25)00304-7.

20. Wattjes MP, Ciccarelli O, Reich DS, Banwell B, Stefano N de, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653–70. https://doi.org/10.1016/S1474-4422(21)00095-8.

21. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: Practical guidelines. Brain. 2019;142:1858–75. https://doi.org/10.1093/brain/awz144.

22. Oechtering J, Schaedelin S, Benkert P, Muller S, Achtnichts L, Vehoff J, et al. Intrathecal immunoglobulin m synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis. Ann Neurol. 2021;90:477–89. https://doi.org/10.1002/ana.26137.

23. Dekeyser C, Hautekeete M, Cambron M, Van Pesch V, Patti F, Kuhle J, et al. Routine CSF parameters as predictors of disease course in multiple sclerosis: An MSBase cohort study. J Neurol Neurosurg Psychiatry. 2024. https://doi.org/10.1136/jnnp-2023-333307.

24. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17:162–73. https://doi.org/10.1016/s1474-4422(17)30470-2.

25. Berek K, Bsteh G, Auer M, Di Pauli F, Grams A, Milosavljevic D, et al. Kappa-free light chains in CSF predict early multiple sclerosis disease activity. Neurol Neuroimmunol Neuroinflamm. 2021;8. https://doi.org/10.1212/NXI.0000000000001005.

26. Vecchio D, Crespi I, Virgilio E, Naldi P, Campisi MP, Serino R, et al. Kappa free light chains could predict early disease course in multiple sclerosis. Mult Scler Relat Disord. 2019;30:81–4. https://doi.org/10.1016/j.msard.2019.02.001.

27. Hegen H, Berek K, Bsteh G, Auer M, Altmann P, Di Pauli F, et al. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study. EBioMedicine. 2023;91:104573. https://doi.org/10.1016/j.ebiom.2023.104573.

28. Voortman MM, Stojakovic T, Pirpamer L, Jehna M, Langkammer C, Scharnagl H, et al. Prognostic value of free light chains lambda and kappa in early multiple sclerosis. Mult Scler. 2017;23:1496–505. https://doi.org/10.1177/1352458516681503.

29. Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult Scler. 2017;23:1309–19. https://doi.org/10.1177/1352458517707265.

30. Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: An expert opinion. J Neurol. 2022;269:5382–94. https://doi.org/10.1007/s00415-022-11193-w.

31. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300. https://doi.org/10.1038/s41582-019-0170-8.

32. Zecca C, Disanto G, Sormani MP, Riccitelli GC, Cianfoni A, Del Grande F, et al. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler. 2016;22:782–91. https://doi.org/10.1177/1352458515599246.

33. Granella F, Tsantes E, Graziuso S, Bazzurri V, Crisi G, Curti E. Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: A retrospective MRI survey. J Neurol. 2019;266:3031–7. https://doi.org/10.1007/s00415-019-09526-3.

34. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152–8. https://doi.org/10.1001/jamaneurol.2014.3537.

35. Brownlee WJ, Altmann DR, Alves Da Mota P, Swanton JK, Miszkiel KA, Wheeler-Kingshott CG, et al. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler. 2017;23:665–74. https://doi.org/10.1177/1352458516663034.

36. Gass A, Rocca MA, Agosta F, Ciccarelli O, Chard D, Valsasina P, et al. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. The Lancet Neurology. 2015;14:443–54. https://doi.org/10.1016/s1474-4422(14)70294-7.

37. Maggi P, Sati P, Nair G, Cortese ICM, Jacobson S, Smith BR, et al. Paramagnetic rim lesions are specific to multiple sclerosis: An international multicenter 3T MRI study. Ann Neurol. 2020;88:1034–42. https://doi.org/10.1002/ana.25877.

38. Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 2019;76:1474–83. https://doi.org/10.1001/jamaneurol.2019.2399.

39. Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142:2787–99. https://doi.org/10.1093/brain/awz212.

40. Sastre-Garriga J, Pareto D, Battaglini M, Rocca MA, Ciccarelli O, Enzinger C, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol. 2020;16:171–82. https://doi.org/10.1038/s41582-020-0314-x.

41. Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857–70. https://doi.org/10.1002/ana.24954.

42. Monreal E, Fernandez-Velasco JI, Alvarez-Lafuente R, Sainz de la Maza S, Garcia-Sanchez MI, Llufriu S, et al. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain. 2024;147:4084–93. https://doi.org/10.1093/brain/awae260.

43. Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10. https://doi.org/10.1212/NXI.0000000000200052.

44. Thebault S, Abdoli M, Fereshtehnejad SM, Tessier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10:10381. https://doi.org/10.1038/s41598-020-67504-6.

45. Ayrignac X, Le Bars E, Duflos C, Hirtz C, Maleska Maceski A, Carra-Dalliere C, et al. Serum GFAP in multiple sclerosis: Correlation with disease type and MRI markers of disease severity. Sci Rep. 2020;10:10923. https://doi.org/10.1038/s41598-020-67934-2.

46. Rovira A, Auger C. Spinal cord in multiple sclerosis: Magnetic resonance imaging features and differential diagnosis. Semin Ultrasound CT MR. 2016;37:396–410. https://doi.org/10.1053/j.sult.2016.05.005.

47. Breckwoldt MO, Gradl J, Hahnel S, Hielscher T, Wildemann B, Diem R, et al. Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: A prospective study in 119 patients. J Neurol. 2017;264:341–9. https://doi.org/10.1007/s00415-016-8353-3.

48. Absinta M, Lassmann H, Trapp BD. Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol. 2020;33:277–85. https://doi.org/10.1097/WCO.0000000000000818.

49. Nijeholt GJ, Bergers E, Kamphorst W, Bot J, Nicolay K, Castelijns JA, et al. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: A correlative study with conventional MRI, histopathology and clinical phenotype. Brain. 2001;124 Pt 1:154–66. https://doi.org/10.1093/brain/124.1.154.

50. Bot JC, Barkhof F, Polman CH, Lycklama a Nijeholt GJ, Groot V de, Bergers E, et al. Spinal cord abnormalities in recently diagnosed MS patients: Added value of spinal MRI examination. Neurology. 2004;62:226–33. https://doi.org/10.1212/wnl.62.2.226.

51. Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 2013;269:542–52.

52. Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: An update. Clin Neuroradiol. 2015;25 Suppl 2:157–65. https://doi.org/10.1007/s00062-015-0430-y.

53. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17. https://doi.org/10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q.

54. Kearney H, Miller DH, Ciccarelli O. Spinal cord MRI in multiple sclerosis–diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015;11:327–38. https://doi.org/10.1038/nrneurol.2015.80.

55. Ouellette R, Treaba CA, Granberg T, Herranz E, Barletta V, Mehndiratta A, et al. 7 t imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. Brain. 2020;143:2973–87. https://doi.org/10.1093/brain/awaa249.

56. Cohen AB, Neema M, Arora A, Dell’oglio E, Benedict RH, Tauhid S, et al. The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging. 2012;22:122–8. https://doi.org/10.1111/j.1552-6569.2011.00589.x.

57. Healy BC, Arora A, Hayden DL, Ceccarelli A, Tauhid SS, Neema M, et al. Approaches to normalization of spinal cord volume: Application to multiple sclerosis. J Neuroimaging. 2012;22:e12–9. https://doi.org/10.1111/j.1552-6569.2011.00629.x.

58. Henmar S, Simonsen EB, Berg RW. What are the gray and white matter volumes of the human spinal cord? J Neurophysiol. 2020;124:1792–7. https://doi.org/10.1152/jn.00413.2020.

59. Johnson MC, Pierson ER, Spieker AJ, Nielsen AS, Posso S, Kita M, et al. Distinct t cell signatures define subsets of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e278. https://doi.org/10.1212/NXI.0000000000000278.

60. Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, et al. Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018;83:283–94. https://doi.org/10.1002/ana.25146.

61. Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, et al. Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018;83:283–94. https://doi.org/10.1002/ana.25146.

62. Fog T. Topographic distribution of plaques in the spinal cord in multiple sclerosis. Archives of Neurology & Psychiatry. 1950;63:382–414.

63. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol. 1978;4:151–62. https://doi.org/10.1111/j.1365-2990.1978.tb00555.x.

64. Waldman AD, Catania C, Pisa M, Jenkinson M, Lenardo M, DeLuca GC. Histopathological characterization of staged lesion topography in the multiple sclerosis spinal cord. medRxiv. 2022.

65. Jensen-Kondering U, Larsen N, Huhndorf M, Jansen O, Luddecke R, Sturner K, et al. Central vein sign in patients with inflammatory lesion of the upper cervical spinal cord on susceptibility weighted imaging at 3 tesla. Preliminary results. Magn Reson Imaging. 2022;93:11–4. https://doi.org/10.1016/j.mri.2022.07.013.

66. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337–41. https://doi.org/10.1038/nature14432.

67. Dupont G, Schmidt C, Yilmaz E, Oskouian RJ, Macchi V, Caro R de, et al. Our current understanding of the lymphatics of the brain and spinal cord. Clin Anat. 2019;32:117–21. https://doi.org/10.1002/ca.23308.

68. Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, Viar KE, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci. 2018;21:1380–91. https://doi.org/10.1038/s41593-018-0227-9.

69. Kearney H, Altmann DR, Samson RS, Yiannakas MC, Wheeler-Kingshott CA, Ciccarelli O, et al. Cervical cord lesion load is associated with disability independently from atrophy in MS. Neurology. 2015;84:367–73. https://doi.org/10.1212/WNL.0000000000001186.

70. Zahid M, Busmail A, Penumetcha SS, Ahluwalia S, Irfan R, Khan SA, et al. Tumor necrosis factor alpha blockade and multiple sclerosis: Exploring new avenues. Cureus. 2021;13:e18847. https://doi.org/10.7759/cureus.18847.

71. Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol. 1997;76:105–11. https://doi.org/10.1016/s0165-5728(97)00034-9.

72. Correale J, Halfon MJ, Jack D, Rubstein A, Villa A. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103264. https://doi.org/10.1016/j.msard.2021.103264.

73. Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Barkhof F, et al. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: A 5-year, multicentre study. J Neurol Neurosurg Psychiatry. 2023;94:10–8. https://doi.org/10.1136/jnnp-2022-329854.

74. Goverman J. Autoimmune t cell responses in the central nervous system. Nat Rev Immunol. 2009;9:393–407. https://doi.org/10.1038/nri2550.

75. Johnson MC, Pierson ER, Spieker AJ, Nielsen AS, Posso S, Kita M, et al. Distinct t cell signatures define subsets of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e278. https://doi.org/10.1212/NXI.0000000000000278.

76. Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. The American Journal of Pathology. 2000;157:637–45. https://doi.org/10.1016/s0002-9440(10)64574-9.

77. Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D, et al. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol. 2009;66:1531–6. https://doi.org/10.1001/archneurol.2009.278.

78. DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, Bird S, et al. Casting light on multiple sclerosis heterogeneity: The role of HLA-DRB1 on spinal cord pathology. Brain. 2013;136 Pt 4:1025–34. https://doi.org/10.1093/brain/awt031.

79. Qiu W, Raven S, James I, Luo Y, Wu J, Castley A, et al. Spinal cord involvement in multiple sclerosis: A correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci. 2011;300:114–9. https://doi.org/10.1016/j.jns.2010.09.006.

80. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–21. https://doi.org/10.1002/ana.24497.

81. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010;133:2983–98. https://doi.org/10.1093/brain/awq250.

82. Luchetti S, Fransen NL, Eden CG van, Ramaglia V, Mason M, Huitinga I. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135:511–28. https://doi.org/10.1007/s00401-018-1818-y.

83. Neumann B, Foerster S, Zhao C, Bodini B, Reich DS, Bergles DE, et al. Problems and pitfalls of identifying remyelination in multiple sclerosis. Cell Stem Cell. 2020;26:617–9. https://doi.org/10.1016/j.stem.2020.03.017.

84. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: Remyelination of nascent lesions. Ann Neurol. 1993;33:137–51. https://doi.org/10.1002/ana.410330203.

85. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler. 1997;3:133–6. https://doi.org/10.1177/135245859700300213.

86. Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol. 2008;201-202:200–11. https://doi.org/10.1016/j.jneuroim.2008.05.034.

87. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain. 2002;125 Pt 2:338–49. https://doi.org/10.1093/brain/awf031.

88. Moccia M, Ruggieri S, Ianniello A, Toosy A, Pozzilli C, Ciccarelli O. Advances in spinal cord imaging in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419840593. https://doi.org/10.1177/1756286419840593.

89. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by t(h)1 and t(h)17 cells. Nat Med. 2008;14:337–42. https://doi.org/10.1038/nm1715.

90. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S. Meningeal t cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol. 2010;68:465–76. https://doi.org/10.1002/ana.22054.

91. Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castillo J, Rio J, et al. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018;24:301–12. https://doi.org/10.1177/1352458517697830.

92. Brex PA, O’Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology. 1999;53:1184–90. https://doi.org/10.1212/wnl.53.6.1184.

93. Trotter JL, Wegescheide CL, Garvey WF. Regional studies of myelin proteins in human brain and spinal cord. Neurochem Res. 1984;9:133–46. https://doi.org/10.1007/BF00967665.

94. Eden D, Gros C, Badji A, Dupont SM, De Leener B, Maranzano J, et al. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain. 2019;142:633–46. https://doi.org/10.1093/brain/awy352.

95. Gilmore CP, Bo L, Owens T, Lowe J, Esiri MM, Evangelou N. Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol. 2006;16:202–8. https://doi.org/10.1111/j.1750-3639.2006.00018.x.

96. Gilmore CP, Donaldson I, Bo L, Owens T, Lowe J, Evangelou N. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: A comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry. 2009;80:182–7. https://doi.org/10.1136/jnnp.2008.148767.

97. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128 Pt 11:2705–12. https://doi.org/10.1093/brain/awh641.

98. Pardini M, Brown JWL, Magliozzi R, Reynolds R, Chard DT. Surface-in pathology in multiple sclerosis: A new view on pathogenesis? Brain. 2021;144:1646–54. https://doi.org/10.1093/brain/awab025.

99. Combes B, Kerbrat A, Ferre JC, Callot V, Maranzano J, Badji A, et al. Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study. Mult Scler. 2019;25:1113–23. https://doi.org/10.1177/1352458518781999.

100. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994;117 ( Pt 4):759–65. https://doi.org/10.1093/brain/117.4.759.

101. Laule C, Vavasour IM, Zhao Y, Traboulsee AL, Oger J, Vavasour JD, et al. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler. 2010;16:670–7. https://doi.org/10.1177/1352458510365586.

102. Lee J, Hyun JW, Lee J, Choi EJ, Shin HG, Min K, et al. So you want to image myelin using MRI: An overview and practical guide for myelin water imaging. J Magn Reson Imaging. 2021;53:360–73. https://doi.org/10.1002/jmri.27059.

103. Mottershead JP, Schmierer K, Clemence M, Thornton JS, Scaravilli F, Barker GJ, et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis–a post-mortem study of the spinal cord. J Neurol. 2003;250:1293–301. https://doi.org/10.1007/s00415-003-0192-3.

104. Thorpe JW, Kidd D, Moseley IF, Kenndall BE, Thompson AJ, MacManus DG, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 1996;46:373–8. https://doi.org/10.1212/wnl.46.2.373.

105. Ciccarelli O, Altmann DR, McLean MA, Wheeler-Kingshott CA, Wimpey K, Miller DH, et al. Spinal cord repair in MS: Does mitochondrial metabolism play a role? Neurology. 2010;74:721–7. https://doi.org/10.1212/WNL.0b013e3181d26968.

106. Freund P, Wheeler-Kingshott C, Jackson J, Miller D, Thompson A, Ciccarelli O. Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. Mult Scler. 2010;16:1193–202. https://doi.org/10.1177/1352458510376180.

107. Théaudin M, Saliou G, Ducot B, Deiva K, Denier C, Adams D, et al. Short-term evolution of spinal cord damage in multiple sclerosis: A diffusion tensor MRI study. Neuroradiology. 2012;54:1171–8. https://doi.org/10.1007/s00234-012-1057-1.

108. Klawiter EC, Schmidt RE, Trinkaus K, Liang HF, Budde MD, Naismith RT, et al. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. Neuroimage. 2011;55:1454–60. https://doi.org/10.1016/j.neuroimage.2011.01.007.

109. Toosy AT, Kou N, Altmann D, Wheeler-Kingshott CA, Thompson AJ, Ciccarelli O. Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis. Neurology. 2014;83:1321–5. https://doi.org/10.1212/WNL.0000000000000857.

110. Naismith RT, Xu J, Klawiter EC, Lancia S, Tutlam NT, Wagner JM, et al. Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. Neurology. 2013;80:2201–9. https://doi.org/10.1212/WNL.0b013e318296e8f1.

111. Oh J, Saidha S, Chen M, Smith SA, Prince J, Jones C, et al. Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. Neurology. 2013;80:540–7. https://doi.org/10.1212/WNL.0b013e31828154c5.

112. Kearney H, Schneider T, Yiannakas MC, Altmann DR, Wheeler-Kingshott CA, Ciccarelli O, et al. Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:608–14. https://doi.org/10.1136/jnnp-2014-308241.

113. Laule C, Moore GRW. Myelin water imaging to detect demyelination and remyelination and its validation in pathology. Brain Pathol. 2018;28:750–64. https://doi.org/10.1111/bpa.12645.

114. Laule C, Yung A, Pavolva V, Bohnet B, Kozlowski P, Hashimoto SA, et al. High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report. Mult Scler. 2016;22:1485–9. https://doi.org/10.1177/1352458515624559.

115. Ljungberg E, Vavasour I, Tam R, Yoo Y, Rauscher A, Li DKB, et al. Rapid myelin water imaging in human cervical spinal cord. Magn Reson Med. 2017;78:1482–7. https://doi.org/10.1002/mrm.26551.

116. Kolind S, Seddigh A, Combes A, Russell-Schulz B, Tam R, Yogendrakumar V, et al. Brain and cord myelin water imaging: A progressive multiple sclerosis biomarker. Neuroimage Clin. 2015;9:574–80. https://doi.org/10.1016/j.nicl.2015.10.002.

117. Vavasour IM, Laule C, Li DK, Oger J, Moore GR, Traboulsee A, et al. Longitudinal changes in myelin water fraction in two MS patients with active disease. J Neurol Sci. 2009;276:49–53. https://doi.org/10.1016/j.jns.2008.08.022.

118. Vargas WS, Monohan E, Pandya S, Raj A, Vartanian T, Nguyen TD, et al. Measuring longitudinal myelin water fraction in new multiple sclerosis lesions. Neuroimage Clin. 2015;9:369–75. https://doi.org/10.1016/j.nicl.2015.09.003.

119. Levesque IR, Giacomini PS, Narayanan S, Ribeiro LT, Sled JG, Arnold DL, et al. Quantitative magnetization transfer and myelin water imaging of the evolution of acute multiple sclerosis lesions. Magn Reson Med. 2010;63:633–40. https://doi.org/10.1002/mrm.22244.

120. Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained b-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Multiple Sclerosis Journal. 2022;28:910–24.

121. Martin AR, Aleksanderek I, Cohen-Adad J, Tarmohamed Z, Tetreault L, Smith N, et al. Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI. Neuroimage Clin. 2016;10:192–238. https://doi.org/10.1016/j.nicl.2015.11.019.

122. Reali C, Magliozzi R, Roncaroli F, Nicholas R, Howell OW, Reynolds R. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol. 2020;30:779–93. https://doi.org/10.1111/bpa.12841.

123. Hoftberger R, Lassmann H, Berger T, Reindl M. Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept. Nat Rev Neurol. 2022;18:681–8. https://doi.org/10.1038/s41582-022-00700-2.

124. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17. https://doi.org/10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q.

125. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32–46. https://doi.org/10.1002/ana.21524.

126. Cramer SP, Modvig S, Simonsen HJ, Frederiksen JL, Larsson HB. Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain. 2015;138 Pt 9:2571–83. https://doi.org/10.1093/brain/awv203.

127. Oechtering J, Lincke T, Schaedelin S, Decard BF, Maceski A, Orleth A, et al. Intrathecal IgM synthesis is associated with spinal cord manifestation and neuronal injury in early MS. Ann Neurol. 2022. https://doi.org/10.1002/ana.26348.

128. Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168–74. https://doi.org/10.1016/j.msard.2019.01.038.

129. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain. 2006;129 Pt 6:1507–16. https://doi.org/10.1093/brain/awl074.

130. Bergers E, Bot JC, De Groot CJ, Polman CH, Lycklama a Nijeholt GJ, Castelijns JA, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology. 2002;59:1766–71. https://doi.org/10.1212/01.wnl.0000036566.00866.26.

131. Giovannoni G, Knappertz V, Steinerman JR, Tansy AP, Li T, Krieger S, et al. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology. 2020;95:e1027–40. https://doi.org/10.1212/wnl.0000000000010284.

132. Lukas C, Knol DL, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:410–8. https://doi.org/10.1136/jnnp-2014-308021.

133. Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K. Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol. 2018;28:334–48. https://doi.org/10.1111/bpa.12516.

134. Bot JC, Blezer EL, Kamphorst W, Lycklama ANGJ, Ader HJ, Castelijns JA, et al. The spinal cord in multiple sclerosis: Relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology. 2004;233:531–40. https://doi.org/10.1148/radiol.2332031572.

135. Weeda MM, Middelkoop SM, Steenwijk MD, Daams M, Amiri H, Brouwer I, et al. Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects. Neuroimage Clin. 2019;24:101962. https://doi.org/10.1016/j.nicl.2019.101962.

136. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced n-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901.

137. Song SK, Sun SW, Ju WK, Lin SJ, Cross AH, Neufeld AH. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage. 2003;20:1714–22. https://doi.org/10.1016/j.neuroimage.2003.07.005.

138. DeBoy CA, Zhang J, Dike S, Shats I, Jones M, Reich DS, et al. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain. 2007;130 Pt 8:2199–210. https://doi.org/10.1093/brain/awm122.

139. Grussu F, Schneider T, Tur C, Yates RL, Tachrount M, Ianus A, et al. Neurite dispersion: A new marker of multiple sclerosis spinal cord pathology? Ann Clin Transl Neurol. 2017;4:663–79. https://doi.org/10.1002/acn3.445.

140. Varhaug KN, Torkildsen O, Myhr KM, Vedeler CA. Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol. 2019;10:338. https://doi.org/10.3389/fneur.2019.00338.

141. Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141:2382–91. https://doi.org/10.1093/brain/awy154.

142. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56:407–15. https://doi.org/10.1002/ana.20202.

143. Evangelou N, DeLuca GC, Owens T, Esiri MM. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain. 2005;128 Pt 1:29–34. https://doi.org/10.1093/brain/awh323.

144. Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: A prospective cohort study. J Neurol. 2022. https://doi.org/10.1007/s00415-022-11118-7.

145. De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868–76. https://doi.org/10.1212/WNL.0b013e3181e24136.

146. Weeda MM, Zywicki S, Brouwer I, Moraal B, Killestein J, Gallo P, et al. Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study. Mult Scler Relat Disord. 2022;60:103713. https://doi.org/10.1016/j.msard.2022.103713.

147. Andelova M, Uher T, Krasensky J, Sobisek L, Kusova E, Srpova B, et al. Additive effect of spinal cord volume, diffuse and focal cord pathology on disability in multiple sclerosis. Front Neurol. 2019;10:820. https://doi.org/10.3389/fneur.2019.00820.

148. Daams M, Weiler F, Steenwijk MD, Hahn HK, Geurts JJ, Vrenken H, et al. Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability. Mult Scler. 2014;20:1860–5. https://doi.org/10.1177/1352458514533399.

149. Mina Y, Azodi S, Dubuche T, Andrada F, Osuorah I, Ohayon J, et al. Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability. Neuroimage Clin. 2021;30:102680. https://doi.org/10.1016/j.nicl.2021.102680.

150. Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol. 2023;80:702–13. https://doi.org/10.1001/jamaneurol.2023.1184.

151. Bonacchi R, Pagani E, Meani A, Cacciaguerra L, Preziosa P, De Meo E, et al. Clinical relevance of multiparametric MRI assessment of cervical cord damage in multiple sclerosis. Radiology. 2020;296:605–15. https://doi.org/10.1148/radiol.2020200430.

152. Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, et al. Preferential spinal cord volume loss in primary progressive multiple sclerosis. Mult Scler. 2019;25:947–57. https://doi.org/10.1177/1352458518775006.

153. Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira A, et al. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology. 2019;93:e1852–66. https://doi.org/10.1212/WNL.0000000000008466.

154. Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study. Neurology. 2018;91:e153–61. https://doi.org/10.1212/WNL.0000000000005772.

155. Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, et al. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: A 36-month real-world study. J Neurol. 2018;265:2851–60. https://doi.org/10.1007/s00415-018-9070-x.

156. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The Lancet. 2018;391:1622–36. https://doi.org/10.1016/s0140-6736(18)30481-1.

157. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152–8. https://doi.org/10.1001/jamaneurol.2014.3537.

158. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323:469–75. https://doi.org/10.1124/jpet.107.127183.

159. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145:101–7. https://doi.org/10.1111/j.1365-2249.2006.03094.x.

160. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull. 2007;74:307–16. https://doi.org/10.1016/j.brainresbull.2007.06.023.

161. Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol. 2008;201-202:200–11. https://doi.org/10.1016/j.jneuroim.2008.05.034.

162. Rocca MA, Preziosa P, Filippi M. What role should spinal cord MRI take in the future of multiple sclerosis surveillance? Expert Rev Neurother. 2020;20:783–97. https://doi.org/10.1080/14737175.2020.1739524.

163. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: Application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (rebif) treatment trial. J Neurol Neurosurg Psychiatry. 2003;74:1090–4. https://doi.org/10.1136/jnnp.74.8.1090.

164. Dupuy SL, Khalid F, Healy BC, Bakshi S, Neema M, Tauhid S, et al. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging. 2016;16:56. https://doi.org/10.1186/s12880-016-0158-4.

165. Singhal T, Tauhid S, Hurwitz S, Neema M, Bakshi R. The effect of glatiramer acetate on spinal cord volume in relapsing-remitting multiple sclerosis. J Neuroimaging. 2017;27:33–6. https://doi.org/10.1111/jon.12378.

166. Ingram G, Loveless S, Howell OW, Hakobyan S, Dancey B, Harris CL, et al. Complement activation in multiple sclerosis plaques: An immunohistochemical analysis. Acta Neuropathol Commun. 2014;2:53. https://doi.org/10.1186/2051-5960-2-53.

167. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology. 2003;60:44–51. https://doi.org/10.1212/wnl.60.1.44.

168. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–84. https://doi.org/10.1016/s0140-6736(15)01314-8.

169. Kearney H, Miller DH, Ciccarelli O. Spinal cord MRI in multiple sclerosis–diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015;11:327–38. https://doi.org/10.1038/nrneurol.2015.80.

170. Bot JC, Barkhof F, Polman CH, Lycklama a Nijeholt GJ, Groot V de, Bergers E, et al. Spinal cord abnormalities in recently diagnosed MS patients: Added value of spinal MRI examination. Neurology. 2004;62:226–33. https://doi.org/10.1212/wnl.62.2.226.

171. Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 2013;269:542–52.

172. Brex PA, O’Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology. 1999;53:1184–90. https://doi.org/10.1212/wnl.53.6.1184.

173. Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castillo J, Rio J, et al. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018;24:301–12. https://doi.org/10.1177/1352458517697830.

174. Brownlee WJ. Do spinal cord lesions matter in patients with clinically isolated syndrome and early MS? Mult Scler. 2018;24:430–1. https://doi.org/10.1177/1352458517749048.

175. Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG, Amato MP, Banwell B, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. The Lancet Neurology. 2019;18:185–97. https://doi.org/10.1016/s1474-4422(18)30460-5.

176. Zurawski J, Glanz BI, Healy BC, Tauhid S, Khalid F, Chitnis T, et al. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019;403:38–43. https://doi.org/10.1016/j.jns.2019.04.023.

177. Vargas MI, Delavelle J, Kohler R, Becker CD, Lovblad K. Brain and spine MRI artifacts at 3Tesla. J Neuroradiol. 2009;36:74–81. https://doi.org/10.1016/j.neurad.2008.08.001.

178. Ladd ME, Bachert P, Meyerspeer M, Moser E, Nagel AM, Norris DG, et al. Pros and cons of ultra-high-field MRI/MRS for human application. Prog Nucl Magn Reson Spectrosc. 2018;109:1–50. https://doi.org/10.1016/j.pnmrs.2018.06.001.

179. Stankiewicz JM, Glanz BI, Healy BC, Arora A, Neema M, Benedict RH, et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011;21:e50–6. https://doi.org/10.1111/j.1552-6569.2009.00449.x.

180. Wattjes MP, Barkhof F. High field MRI in the diagnosis of multiple sclerosis: High field-high yield? Neuroradiology. 2009;51:279–92. https://doi.org/10.1007/s00234-009-0512-0.

181. Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, et al. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 t and 3 t MRI study. J Neurol Sci. 2009;279:99–105. https://doi.org/10.1016/j.jns.2008.11.009.

182. Massire A, Taso M, Besson P, Guye M, Ranjeva JP, Callot V. High-resolution multi-parametric quantitative magnetic resonance imaging of the human cervical spinal cord at 7T. Neuroimage. 2016;143:58–69. https://doi.org/10.1016/j.neuroimage.2016.08.055.

183. Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: A consensus statement from the north american imaging in multiple sclerosis cooperative. Nat Rev Neurol. 2016;12:714–22. https://doi.org/10.1038/nrneurol.2016.166.

184. Absinta M, Sati P, Reich DS. Advanced MRI and staging of multiple sclerosis lesions. Nature Reviews Neurology. 2016;12:358.

185. Ng Kee Kwong KC, Mollison D, Meijboom R, York EN, Kampaite A, Thrippleton MJ, et al. The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis. PLoS One. 2021;16:e0256845. https://doi.org/10.1371/journal.pone.0256845.

186. Dula AN, Pawate S, Dethrage LM, Conrad BN, Dewey BE, Barry RL, et al. Chemical exchange saturation transfer of the cervical spinal cord at 7 t. NMR Biomed. 2016;29:1249–57. https://doi.org/10.1002/nbm.3581.

187. Winkler SA, Schmitt F, Landes H, Bever J de, Wade T, Alejski A, et al. Gradient and shim technologies for ultra high field MRI. Neuroimage. 2018;168:59–70. https://doi.org/10.1016/j.neuroimage.2016.11.033.

188. Sengupta S, Welch EB, Zhao Y, Foxall D, Starewicz P, Anderson AW, et al. Dynamic B0 shimming at 7 t. Magn Reson Imaging. 2011;29:483–96. https://doi.org/10.1016/j.mri.2011.01.002.

189. De Graaf RA, Brown PB, McIntyre S, Rothman DL, Nixon TW. Dynamic shim updating (DSU) for multislice signal acquisition. Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine. 2003;49:409–16.

190. Zecca C, Disanto G, Sormani MP, Riccitelli GC, Cianfoni A, Del Grande F, et al. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler. 2016;22:782–91. https://doi.org/10.1177/1352458515599246.

191. Hamilton J, Franson D, Seiberlich N. Recent advances in parallel imaging for MRI. Prog Nucl Magn Reson Spectrosc. 2017;101:71–95. https://doi.org/10.1016/j.pnmrs.2017.04.002.

192. Barry RL, Vannesjo SJ, By S, Gore JC, Smith SA. Spinal cord MRI at 7T. Neuroimage. 2018;168:437–51. https://doi.org/10.1016/j.neuroimage.2017.07.003.

193. Vannesjo SJ, Clare S, Kasper L, Tracey I, Miller KL. A method for correcting breathing-induced field fluctuations in T2*-weighted spinal cord imaging using a respiratory trace. Magn Reson Med. 2019;81:3745–53. https://doi.org/10.1002/mrm.27664.

194. Heeswijk RB van, Bonanno G, Coppo S, Coristine A, Kober T, Stuber M. Motion compensation strategies in magnetic resonance imaging. Critical Reviews™ in Biomedical Engineering. 2012;40.

195. Sati P. Diagnosis of multiple sclerosis through the lens of ultra-high-field MRI. J Magn Reson. 2018;291:101–9. https://doi.org/10.1016/j.jmr.2018.01.022.

196. Smith SA, Dortch RD, Barry RL, Gore JC. Ultra-high field spinal cord imaging. In: Quantitative MRI of the spinal cord. 2014. p. 106–19. https://doi.org/10.1016/b978-0-12-396973-6.00008-3.

197. Fries P, Morelli JN, Lux F, Tillement O, Schneider G, Buecker A. The issues and tentative solutions for contrast-enhanced magnetic resonance imaging at ultra-high field strength. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6:559–73. https://doi.org/10.1002/wnan.1291.

198. Hagberg GE, Scheffler K. Effect of r(1) and r(2) relaxivity of gadolinium-based contrast agents on the t(1)-weighted MR signal at increasing magnetic field strengths. Contrast Media Mol Imaging. 2013;8:456–65. https://doi.org/10.1002/cmmi.1565.

199. Harrison DM, Wang KY, Fiol J, Naunton K, Royal 3rd W., Hua J, et al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. J Neuroimaging. 2017;27:461–8. https://doi.org/10.1111/jon.12444.

200. Heilmaier C, Theysohn JM, Maderwald S, Kraff O, Ladd ME, Ladd SC. A large-scale study on subjective perception of discomfort during 7 and 1.5 t MRI examinations. Bioelectromagnetics. 2011;32:610–9. https://doi.org/10.1002/bem.20680.

201. Friebe B, Wollrab A, Thormann M, Fischbach K, Ricke J, Grueschow M, et al. Sensory perceptions of individuals exposed to the static field of a 7T MRI: A controlled blinded study. J Magn Reson Imaging. 2015;41:1675–81. https://doi.org/10.1002/jmri.24748.

202. Dula AN, Pawate S, Dortch RD, Barry RL, George-Durrett KM, Lyttle BD, et al. Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T. Mult Scler. 2016;22:320–8. https://doi.org/10.1177/1352458515591070.

203. Conrad BN, Barry RL, Rogers BP, Maki S, Mishra A, Thukral S, et al. Multiple sclerosis lesions affect intrinsic functional connectivity of the spinal cord. Brain. 2018;141:1650–64. https://doi.org/10.1093/brain/awy083.

204. Lefeuvre JA, Duan Q, De Zwart J, Gelderen P van, Lehéricy S, Jacobson SG, et al. MRI of the thoracic spinal cord in multiple sclerosis at 7T. In: ACTRIMS forum 2017. ACTRIMS.

205. Witt BR Atlee; Kirkland. 7T MRI shows enlarged anterior vein in the spinal cord of multiple sclerosis patients. ISMRM Proc. 2019.

206. Massire SL Aurélien; Demortiere. High-resolution multiparametric quantitative MRI of the cervical spinal cord at 7T: Preliminary results at the early stage of multiple sclerosis. ISMRM Proc. 2019.

207. Conrad BN, Lyttle BD, Pawate S, Barry RL, Landman BA, Smith SA. Measuring cross sectional area of the spinal cord at 7T: Validating fully automated segmentation. ISMRM Proc. 2015.

208. Rovira A, Wattjes MP, Tintore M, Tur C, Yousry TA, Sormani MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:471–82. https://doi.org/10.1038/nrneurol.2015.106.

209. Geldschlager O, Bosch D, Avdievich NI, Henning A. Ultrahigh-resolution quantitative spinal cord MRI at 9.4T. Magn Reson Med. 2021;85:1013–27. https://doi.org/10.1002/mrm.28455.

210. Ineichen BV, Beck ES, Piccirelli M, Reich DS. New prospects for ultra-high-field magnetic resonance imaging in multiple sclerosis. Invest Radiol. 2021. https://doi.org/10.1097/RLI.0000000000000804.

211. Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain. 2019;142:2276–87. https://doi.org/10.1093/brain/awz156.

212. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler. 2015;21:1013–24. https://doi.org/10.1177/1352458514568827.

213. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17:162–73. https://doi.org/10.1016/s1474-4422(17)30470-2.

214. Rovira A, Wattjes MP, Tintore M, Tur C, Yousry TA, Sormani MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:471–82. https://doi.org/10.1038/nrneurol.2015.106.

215. Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, et al. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 t and 3 t MRI study. J Neurol Sci. 2009;279:99–105. https://doi.org/10.1016/j.jns.2008.11.009.

216. Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, et al. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain. 2020;143:2742–56. https://doi.org/10.1093/brain/awaa231.

217. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. J Neurol. 2020;267:3489–98. https://doi.org/10.1007/s00415-019-09395-w.

218. Prosperini L, Fanelli F, Pozzilli C. Long-term assessment of no evidence of disease activity with natalizumab in relapsing multiple sclerosis. J Neurol Sci. 2016;364:145–7. https://doi.org/10.1016/j.jns.2016.03.025.

219. Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, et al. Early clinical markers of aggressive multiple sclerosis. Brain. 2020;143:1400–13. https://doi.org/10.1093/brain/awaa081.

220. Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: A prospective cohort study. J Neurol. 2022. https://doi.org/10.1007/s00415-022-11118-7.

221. Roquemaurel A de, Galli P, Landais A, Avendano S, Cabre P. Fingolimod for the treatment of multiple sclerosis in french west indies, a real-world study in patients from african ancestry. J Neurol Sci. 2019;402:180–7. https://doi.org/10.1016/j.jns.2019.05.027.

222. Guerra T, Caputo F, Orlando B, Paolicelli D, Trojano M, Iaffaldano P. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years. Neurol Sci. 2021;42:4647–55. https://doi.org/10.1007/s10072-021-05127-z.

223. Henmar S, Simonsen EB, Berg RW. What are the gray and white matter volumes of the human spinal cord? J Neurophysiol. 2020;124:1792–7. https://doi.org/10.1152/jn.00413.2020.

224. Rovaris M, Bozzali M, Santuccio G, Iannucci G, Sormani MP, Colombo B, et al. Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: A study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry. 2000;69:723–7. https://doi.org/10.1136/jnnp.69.6.723.

225. Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, et al. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 t and 3 t MRI study. J Neurol Sci. 2009;279:99–105. https://doi.org/10.1016/j.jns.2008.11.009.

226. Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, et al. Spinal cord lesions in patients with clinically isolated syndrome: A powerful tool in diagnosis and prognosis. Neurology. 2013;80:69–75. https://doi.org/10.1212/WNL.0b013e31827b1a67.

227. Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, et al. MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12:769–74. https://doi.org/10.1177/1352458506070775.

228. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120 ( Pt 11):2059–69. https://doi.org/10.1093/brain/120.11.2059.

229. Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Autoimmun Rev. 2021;20:102826. https://doi.org/10.1016/j.autrev.2021.102826.

230. He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. The Lancet Neurology. 2020;19:307–16. https://doi.org/10.1016/s1474-4422(20)30067-3.

231. Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90:e1805–14. https://doi.org/10.1212/WNL.0000000000005516.

232. Moccia M, Haider L, Eshaghi A, Pavert SHP van de, Brescia Morra V, Patel A, et al. B cells in the CNS at postmortem are associated with worse outcome and cell types in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9. https://doi.org/10.1212/NXI.0000000000001108.

233. Luders E, Steinmetz H, Jancke L. Brain size and grey matter volume in the healthy human brain. Neuroreport. 2002;13:2371–4. https://doi.org/10.1097/01.wnr.0000049603.85580.da.

234. Signoriello E, Landi D, Monteleone F, Sacca F, Nicoletti CG, Buttari F, et al. Fingolimod reduces the clinical expression of active demyelinating lesions in MS. Mult Scler Relat Disord. 2018;20:215–9. https://doi.org/10.1016/j.msard.2018.02.002.

235. Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain. 2019;142:2276–87. https://doi.org/10.1093/brain/awz156.

236. Lauerer M, McGinnis J, Bussas M, El Husseini M, Pongratz V, Engl C, et al. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023. https://doi.org/10.1136/jnnp-2023-331799.

237. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. J Neurol. 2020;267:3489–98. https://doi.org/10.1007/s00415-019-09395-w.

238. Kreiter D, Spee R, Merry A, Hupperts R, Gerlach O. Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study. Mult Scler Relat Disord. 2023;79:104994. https://doi.org/10.1016/j.msard.2023.104994.

239. Henmar S, Simonsen EB, Berg RW. What are the gray and white matter volumes of the human spinal cord? J Neurophysiol. 2020;124:1792–7. https://doi.org/10.1152/jn.00413.2020.

240. Thron AK. Vascular anatomy of the spinal cord: Radioanatomy as the key to diagnosis and treatment. Book. Springer; 2016.

241. Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M. The blood-spinal cord barrier: Morphology and clinical implications. Ann Neurol. 2011;70:194–206. https://doi.org/10.1002/ana.22421.

242. Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol. 1997;76:105–11. https://doi.org/10.1016/s0165-5728(97)00034-9.

243. Goverman J. Autoimmune t cell responses in the central nervous system. Nat Rev Immunol. 2009;9:393–407. https://doi.org/10.1038/nri2550.

244. Wang SV, Schneeweiss S. A framework for visualizing study designs and data observability in electronic health record data. Clin Epidemiol. 2022;14:601–8. https://doi.org/10.2147/CLEP.S358583.

245. He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. The Lancet Neurology. 2020;19:307–16. https://doi.org/10.1016/s1474-4422(20)30067-3.

246. Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90:e1805–14. https://doi.org/10.1212/WNL.0000000000005516.

247. Hauser S, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. B-cell depletion and efficacy outcomes with ofatumumab: Subgroup analysis from the pooled phase 3 ASCLEPIOS i and II trials (2356). Neurology. 2020;94 15 Supplement:2356.

248. Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, et al. Effects of high- and low-efficacy therapy in secondary progressive multiple sclerosis. Neurology. 2021;97:e869–80. https://doi.org/10.1212/WNL.0000000000012354.

249. Stuart EA, King G, Imai K, Ho D. MatchIt: Nonparametric preprocessing for parametric causal inference. Journal of statistical software. 2011.

250. Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: A cohort study. Lancet Neurol. 2017;16:271–81. https://doi.org/10.1016/S1474-4422(17)30007-8.

251. DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, Bird S, et al. Casting light on multiple sclerosis heterogeneity: The role of HLA-DRB1 on spinal cord pathology. Brain. 2013;136 Pt 4:1025–34. https://doi.org/10.1093/brain/awt031.

252. Qiu W, Raven S, James I, Luo Y, Wu J, Castley A, et al. Spinal cord involvement in multiple sclerosis: A correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci. 2011;300:114–9. https://doi.org/10.1016/j.jns.2010.09.006.

253. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain. 2002;125 Pt 2:338–49. https://doi.org/10.1093/brain/awf031.

254. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–21. https://doi.org/10.1002/ana.24497.

255. Filippi M, Brück W, Chard D, Fazekas F, Geurts JJG, Enzinger C, et al. Association between pathological and MRI findings in multiple sclerosis. The Lancet Neurology. 2019;18:198–210. https://doi.org/10.1016/s1474-4422(18)30451-4.

256. Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K. Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol. 2018;28:334–48. https://doi.org/10.1111/bpa.12516.

257. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: A pathological survey of the corticospinal and sensory tracts. Brain. 2004;127 Pt 5:1009–18. https://doi.org/10.1093/brain/awh118.

258. Combes AJE, Clarke MA, O’Grady KP, Schilling KG, Smith SA. Advanced spinal cord MRI in multiple sclerosis: Current techniques and future directions. NeuroImage: Clinical. 2022. https://doi.org/10.1016/j.nicl.2022.103244.

259. Rissanen E, Tuisku J, Rokka J, Paavilainen T, Parkkola R, Rinne JO, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand (1)(1)c-PK11195. J Nucl Med. 2014;55:939–44. https://doi.org/10.2967/jnumed.113.131698.

260. Granella F, Tsantes E, Graziuso S, Bazzurri V, Crisi G, Curti E. Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: A retrospective MRI survey. J Neurol. 2019;266:3031–7. https://doi.org/10.1007/s00415-019-09526-3.

261. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol. 2005;62:865–70. https://doi.org/10.1001/archneur.62.6.865.

262. Oechtering J, Lincke T, Schaedelin S, Decard BF, Maceski A, Orleth A, et al. Intrathecal IgM synthesis is associated with spinal cord manifestation and neuronal injury in early MS. Ann Neurol. 2022. https://doi.org/10.1002/ana.26348.

263. Ozakbas S, Cinar BP, Ozcelik P, Baser H, Kosehasanogullari G. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results. Clin Neurol Neurosurg. 2017;160:27–9. https://doi.org/10.1016/j.clineuro.2017.05.026.

264. Warren KG, Catz I, Jeffrey VM, Carroll DJ. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci. 1986;13:25–30. https://doi.org/10.1017/s0317167100035757.

265. Frequin ST, Barkhof F, Lamers KJ, Hommes OR, Borm GF. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand. 1992;86:291–7. https://doi.org/10.1111/j.1600-0404.1992.tb05088.x.

266. Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, et al. Impact of 3 tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. Mult Scler. 2019;25:352–60. https://doi.org/10.1177/1352458517751647.

267. Hagens MHJ, Burggraaff J, Kilsdonk ID, Vos ML de, Cawley N, Sbardella E, et al. Three-tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study. Neurology. 2018;91:e249–57. https://doi.org/10.1212/WNL.0000000000005825.

268. Reiber H. Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99–107. https://doi.org/10.1177/135245859800400302.

269. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998;4:111–7. https://doi.org/10.1177/135245859800400304.

270. Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kumpfel T, et al. Association of intrathecal immunoglobulin g synthesis with disability worsening in multiple sclerosis. JAMA Neurol. 2019;76:841–9. https://doi.org/10.1001/jamaneurol.2019.0905.

271. Karrenbauer VD, Bedri SK, Hillert J, Manouchehrinia A. Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: A retrospective cohort study. Sci Rep. 2021;11:14987. https://doi.org/10.1038/s41598-021-94423-x.

272. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: Associations with disease course and progression. Mult Scler. 2013;19:577–84. https://doi.org/10.1177/1352458512459684.

273. Klein A, Selter RC, Hapfelmeier A, Berthele A, Muller-Myhsok B, Pongratz V, et al. CSF parameters associated with early MRI activity in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2019;6:e573. https://doi.org/10.1212/NXI.0000000000000573.

274. Magliozzi R, Mazziotti V, Montibeller L, Pisani AI, Marastoni D, Tamanti A, et al. Cerebrospinal fluid IgM levels in association with inflammatory pathways in multiple sclerosis patients. Front Cell Neurosci. 2020;14:569827. https://doi.org/10.3389/fncel.2020.569827.

275. Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, Roldan E, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol. 2003;53:222–6. https://doi.org/10.1002/ana.10441.

276. Villar LM, Sádaba MC, Roldán E, Masjuan J, González-Porqué P, Villarrubia N, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. Journal of Clinical Investigation. 2005;115:187–94. https://doi.org/10.1172/jci22833.

277. Perini P, Ranzato F, Calabrese M, Battistin L, Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77:953–5. https://doi.org/10.1136/jnnp.2005.086116.

278. Ayrignac X, Aouinti S, Vincent T, Carra-Dalliere C, Charif M, Duflos C, et al. Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up. Mult Scler Relat Disord. 2024;89:105747. https://doi.org/10.1016/j.msard.2024.105747.

279. Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol. 2022;21:246–57. https://doi.org/10.1016/S1474-4422(22)00009-6.

280. Canto E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 2019;76:1359–66. https://doi.org/10.1001/jamaneurol.2019.2137.

281. Arroyo-Pereiro P, Garcia-Serrano L, Morandeira F, Urban B, Mas V, Framil M, et al. Kappa free light chains index in multiple sclerosis very long-term prognosis. Front Immunol. 2023;14:1223514. https://doi.org/10.3389/fimmu.2023.1223514.

282. Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, Roldan E, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59:555–9. https://doi.org/10.1212/wnl.59.4.555.

283. Akaishi T, Takahashi T, Fujihara K, Misu T, Nishiyama S, Takai Y, et al. Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis. Mult Scler Relat Disord. 2020;45:102382. https://doi.org/10.1016/j.msard.2020.102382.

284. Rodriguez-Mogeda C, Gool MM van, Mast R van der, Nijland R, Keasberry Z, Bovekamp L van de, et al. Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal b cell presence in MS. Sci Rep. 2024;14:25540. https://doi.org/10.1038/s41598-024-76969-8.

285. Reali C, Magliozzi R, Roncaroli F, Nicholas R, Howell OW, Reynolds R. B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. Brain Pathol. 2020;30:779–93. https://doi.org/10.1111/bpa.12841.

286. Brandle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A. 2016;113:7864–9. https://doi.org/10.1073/pnas.1522730113.

287. Winger RC, Zamvil SS. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc Natl Acad Sci U S A. 2016;113:7696–8. https://doi.org/10.1073/pnas.1609246113.

288. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32–46. https://doi.org/10.1002/ana.21524.

289. Kreiter D, Postma AA, Hupperts R, Gerlach O. Hallmarks of spinal cord pathology in multiple sclerosis. J Neurol Sci. 2024;456:122846. https://doi.org/10.1016/j.jns.2023.122846.

290. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine. 2003;348:15–23.

291. Di Sabatino E, Gaetani L, Sperandei S, Fiacca A, Guercini G, Parnetti L, et al. The no evidence of disease activity (NEDA) concept in MS: Impact of spinal cord MRI. J Neurol. 2022;269:3129–35. https://doi.org/10.1007/s00415-021-10901-2.

292. Tummala S, Singhal T, Oommen VV, Kim G, Khalid F, Healy BC, et al. Spinal cord as an adjunct to brain magnetic resonance imaging in defining "no evidence of disease activity" in multiple sclerosis. Int J MS Care. 2017;19:158–64. https://doi.org/10.7224/1537-2073.2016-068.

293. Ciccarelli O, Barkhof F, Calabrese M, De Stefano N, Eshaghi A, Filippi M, et al. Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis. Neurology. 2024;103:e209444. https://doi.org/10.1212/WNL.0000000000209444.

294. Kreiter D, Spee R, Merry A, Hupperts R, Gerlach O. Effect of high-efficacy disease-modifying treatment on spinal cord lesion formation in multiple sclerosis. Submitted. 2023.

295. Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, et al. Vitamin d as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71:306–14. https://doi.org/10.1001/jamaneurol.2013.5993.

296. Di Filippo M, Gaetani L, Centonze D, Hegen H, Kuhle J, Teunissen CE, et al. Fluid biomarkers in multiple sclerosis: From current to future applications. Lancet Reg Health Eur. 2024;44:101009. https://doi.org/10.1016/j.lanepe.2024.101009.

297. Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu DV, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182:1541–7. https://doi.org/10.4049/jimmunol.182.3.1541.

298. Mahler MR, Sondergaard HB, Buhelt S, Essen MR von, Romme Christensen J, Enevold C, et al. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. Mult Scler Relat Disord. 2020;45:102391. https://doi.org/10.1016/j.msard.2020.102391.

299. Mimpen M, Damoiseaux J, Doorn W van, Rolf L, Muris AH, Hupperts R, et al. Proportions of circulating transitional b cells associate with MRI activity in interferon beta-treated multiple sclerosis patients. J Neuroimmunol. 2021;358:577664. https://doi.org/10.1016/j.jneuroim.2021.577664.

300. Kreiter D, Kalincik T, Hupperts R, Patti F, Spitaleri D, Foschi M, et al. Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: An MSBase registry study. CNS Drugs. 2024;38:921–30. https://doi.org/10.1007/s40263-024-01115-x.

301. Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study. J Neuroimmunol. 2011;234:141–7. https://doi.org/10.1016/j.jneuroim.2011.02.009.

302. Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, et al. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. Neurology. 2017;89:2455–61. https://doi.org/10.1212/WNL.0000000000004716.

303. Trobisch T, Zulji A, Stevens NA, Schwarz S, Wischnewski S, Ozturk M, et al. Cross-regional homeostatic and reactive glial signatures in multiple sclerosis. Acta Neuropathol. 2022;144:987–1003. https://doi.org/10.1007/s00401-022-02497-2.

304. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383–92. https://doi.org/10.1038/nrneurol.2010.72.

305. Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14:265–77. https://doi.org/10.1038/nrn3468.

306. Ota Y, Srinivasan A, Capizzano AA, Bapuraj JR, Kim J, Kurokawa R, et al. Central nervous system systemic lupus erythematosus: Pathophysiologic, clinical, and imaging features. Radiographics. 2022;42:212–32. https://doi.org/10.1148/rg.210045.

307. Corbali O, Chitnis T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. 2023;14:1137998. https://doi.org/10.3389/fneur.2023.1137998.

308. Schmierer K, Wheeler-Kingshott CA, Boulby PA, Scaravilli F, Altmann DR, Barker GJ, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage. 2007;35:467–77. https://doi.org/10.1016/j.neuroimage.2006.12.010.

309. Cramer SP, Simonsen HJ, Varatharaj A, Galea I, Frederiksen JL, Larsson HBW. Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis. Ann Neurol. 2018;83:902–14. https://doi.org/10.1002/ana.25219.

310. Ingrisch M, Sourbron S, Morhard D, Ertl-Wagner B, Kumpfel T, Hohlfeld R, et al. Quantification of perfusion and permeability in multiple sclerosis: Dynamic contrast-enhanced MRI in 3D at 3T. Invest Radiol. 2012;47:252–8. https://doi.org/10.1097/RLI.0b013e31823bfc97.

311. Lavini C, Kramer G, Pieters-den Bos I, Hoekstra O, Marcus JT. MRI protocol optimization for quantitative DCE-MRI of the spine. Magn Reson Imaging. 2017;44:96–103. https://doi.org/10.1016/j.mri.2017.08.010.

312. Clarke MA, Witt AA, Robison RK, Fleishman S, Combes AJE, Houston D, et al. Cervical spinal cord susceptibility-weighted MRI at 7T: Application to multiple sclerosis. Neuroimage. 2023;284:120460. https://doi.org/10.1016/j.neuroimage.2023.120460.

313. Ostini C, Bovis F, Disanto G, Ripellino P, Pravata E, Sacco R, et al. Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis. J Clin Med. 2021;10. https://doi.org/10.3390/jcm10030463.

314. Ruggieri S, Prosperini L, Petracca M, Logoteta A, Tinelli E, De Giglio L, et al. The added value of spinal cord lesions to disability accrual in multiple sclerosis. J Neurol. 2023;270:4995–5003. https://doi.org/10.1007/s00415-023-11829-5.

315. Lim TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, Jones A, Lin AW, et al. Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis. Mult Scler. 2024;30:505–15. https://doi.org/10.1177/13524585241228426.

316. Keegan BM, Absinta M, Cohen-Adad J, Flanagan EP, Henry RG, Klawiter EC, et al. Spinal cord evaluation in multiple sclerosis: Clinical and radiological associations, present and future. Brain Commun. 2024;6:fcae395. https://doi.org/10.1093/braincomms/fcae395.

317. Neurologie NV voor. Multiple sclerose (MS). Richtlijnendatabase. 2021.